ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2021
The Association Between Insulin Resistance, Leptin, and Resistin and Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients with Different Body Mass Indexes.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Increased Leptin Levels in Plasma and Serum in Patients with Metabolic Disorders: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes.BMC endocrine disorders · 2026Article
- Type 2 Diabetes and Hemodialysis: Metabolic Challenges and the Role of Intradialytic Exercise.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- The Predictive Value of Insulin Resistance Surrogates for Diabetic Kidney Disease in Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Impact of HCV elimination on metabolism markers in people living with HIV.Scientific reports · 2025Article
- The Role of Resistin in Macrovascular and Microvascular Complications of Type 2 Diabetes.Life (Basel, Switzerland) · 2025Review
- Exploring the interplay between adipokine-mediated celastrol target genes and T cells in diabetic nephropathy: a mendelian randomization-based causal inference.Diabetology & metabolic syndrome · 2025Article
- Circulating leptin and resistin levels in myocardial infarction patients with insulin resistance.The Journal of international medical research · 2025Article
- Gestational Diabetes Mellitus and Colostral Appetite-Regulating Adipokines.International journal of molecular sciences · 2024Article
- Roles of plasma leptin and resistin in novel subgroups of type 2 diabetes driven by cluster analysis.Lipids in health and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare HOMA-IR, leptin, and resistin as the risk factors for diabetic nephropathy in the type 2 diabetes mellitus (T2DM) patients with different BMI classifications. MATERIALS AND
methodsA total of 309 patients with T2DM were enrolled in this cross-sectional study. All participants were divided into three groups according to BMI: the normal weight group (18.5 kg/m
resultsHigher HOMA-IR, leptin and resistin levels were found to be the risk factors for diabetic nephropathy when we made comparisons in the total population (
conclusionHigher insulin resistance, leptin and resistin levels were observed as risk factors for diabetic nephropathy in T2DM patients with lower BMI. These were not obvious in the overweight and obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.